Cargando…
Identification of Appropriate Endogenous Biomarker for Risk Assessment of Multidrug and Toxin Extrusion Protein‐Mediated Drug‐Drug Interactions in Healthy Volunteers
Endogenous biomarkers are emerging to advance clinical drug‐drug interaction (DDI) risk assessment in drug development. Twelve healthy subjects received a multidrug and toxin exclusion protein (MATE) inhibitor (pyrimethamine, 10, 25, and 75 mg) in a crossover fashion to identify an appropriate endog...
Autores principales: | Miyake, Takeshi, Kimoto, Emi, Luo, Lina, Mathialagan, Sumathy, Horlbogen, Lauren M., Ramanathan, Ragu, Wood, Linda S., Johnson, Jillian G., Le, Vu H., Vourvahis, Manoli, Rodrigues, A. David, Muto, Chieko, Furihata, Kenichi, Sugiyama, Yuichi, Kusuhara, Hiroyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891601/ https://www.ncbi.nlm.nih.gov/pubmed/32866300 http://dx.doi.org/10.1002/cpt.2022 |
Ejemplares similares
-
Dose‐Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs
por: Mori, Daiki, et al.
Publicado: (2020) -
Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous Biomarkers
por: Vourvahis, Manoli, et al.
Publicado: (2022) -
A literature review of liver function test elevations in rifampin drug–drug interaction studies
por: Ibrahim, Sherry M., et al.
Publicado: (2022) -
Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug–Drug Interaction Studies
por: Elmeliegy, Mohamed, et al.
Publicado: (2020) -
The Effects of Boceprevir and Telaprevir on the Pharmacokinetics of Maraviroc: An Open-Label, Fixed-Sequence Study in Healthy Volunteers
por: Vourvahis, Manoli, et al.
Publicado: (2014)